MedTrace Logo

Trial of EXenatide in Acute Ischaemic Stroke

NCT03287076 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2021-09-14

No results posted yet for this study

Summary

A multicentre, randomised controlled Trial of Exenatide versus standard care in Acute Ischemic Stroke

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Exenatide Injection

5μg subcutaneously twice daily for five days, commencing within 9 hours of symptom onset

Sponsors & Collaborators

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • Monash University

    collaborator OTHER

  • Neuroscience Trials Australia

    lead OTHER

Principal Investigators

  • Christopher Bladin · The Florey Institute of Neuroscience & Mental Health Melbourne Brain Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-23
Primary Completion
2021-10-04
Completion
2021-12-31
FDA Drug
Yes

Countries

  • Australia
  • Finland
  • New Zealand

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03287076 on ClinicalTrials.gov